Metastatic Breast Cancer (MBC), a more advanced and invasive form of breast cancer, affects approximately 170,000 women in the US alone and remains a leading cause of cancer-related deaths globally. Though recent improvements in screening are already helping achieve better health outcomes, there is still a critical need for new therapies to help further reduce the impact of the disease, which currently remains incurable. Driven by this goal, our scientists are working every day, applying their expertise and cutting-edge technology to design and develop innovative therapeutic candidates. Learn more about a discovery that will hopefully bring them one step closer to a potential advancement in first-line care for certain forms of MBC: https://lnkd.in/d-D-hje7 #Oncology #BreastCancer #CancerResearch #BehindTheScience
About us
We’re celebrating over 175 years of daring scientific innovation—and we’re not done yet. Let’s outdo yesterday. Protect your health at PfizerForAll.com For additional information on our guidelines, please visit http://www.pfizer.com/community-guidelines
- Website
-
https://www.pfizer.com/?source=Linkedin
External link for Pfizer
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- New York, New York
- Type
- Public Company
- Specialties
- To apply science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe and effective and affordable medicines and health care services to the people who need them.
Locations
Employees at Pfizer
Updates
-
Here at Pfizer, we pursue scientific breakthroughs that change patients’ lives, but none of our innovations would reach the patients in need without our manufacturing powerhouse — Pfizer Global Supply or PGS. Our high-tech and robust pharmaceutical manufacturing infrastructure combined with the hard work of our dedicated PGS colleagues makes it possible for Pfizer to deliver medicines and vaccines to patients where and when they need them. Watch Pfizer’s US supply network in action. https://lnkd.in/gjVT3eKV
-
-
A potential hidden driver of cachexia is a stress signal called GDF-15. Elevated levels of GDF-15 are linked to more severe symptoms of cachexia, including appetite loss, fatigue, and muscle wasting. In our latest explainer, we describe what GDF-15 is and how new research aims to understand the underlying biology of this condition. Click here to learn about cachexia, who it affects, and some of our preliminary findings: https://lnkd.in/gfq8wj2u
What is GDF-15?
-
2025 was a strong year for Pfizer and we continued to deliver breakthroughs that change patients' lives. We are looking ahead to 2026 with focus, confidence, and an unwavering commitment to patients.
We just shared our Q4 and full-year results, and I couldn't be more proud of what we delivered. I'm even more optimistic about what's ahead. In 2026, we're pursuing up to twenty pivotal studies across our portfolio. And with Metsera, we're moving fast in obesity, including today's encouraging new Phase 2 data for our ultra-long-acting GLP-1. This is Pfizer at our best. We can't wait to share more progress soon.
-
Hanna’s interest in science began at an early age, influenced by her father’s career. Now working at Pfizer as a scientist herself, she brings purpose to her work, driven by the belief that determination and scientific rigor can make a meaningful difference for patients. That mindset is central to the work we do and the people who make it possible. #Science #Innovation
-
IOIBD and Pfizer launched something powerful: The Empowering Women in IBD Leadership Program, a global initiative aimed to elevate women shaping the future of GI. The program kicked off at UEGW in October. Here, the mentors, mentees and guest speaker share why elevating emerging leaders matters, what skills they’re building, and how amplifying women’s voices can help the next generation “fly.” Here’s to building a more inclusive, confident, and connected community of female leaders in IBD. The momentum continues this February at the next program session at ECCO in Stockholm! #WomenInIBD #IOIBD #Pfizer #LeadershipInGI #UEGW2025 #ECCO2026
-
New year, fresh start. Many common new year’s resolutions focus on losing weight, by exercising more, drinking less, and adopting healthier eating habits. Pfizer knows that the foods we eat play a major role staying healthy all year long. Kick off the new year with three food habits that can boost your health and create positive changes. (No new year’s diet required!) https://lnkd.in/enGGVaMq
-
The immune system is one of the most complex and vital systems in the human body. It functions as a coordinated defense network, identifying, targeting, and eliminating pathogens to help maintain health and prevent disease. This explainer breaks down the key components of the immune system and how they work together to help keep you healthy. #ImmuneSystem #Immunology
Key Components Of The Immune System
-
Pfizer reposted this
I’m thrilled to announce that the first patients have been dosed in new Phase 3 studies for two recent additions to the Pfizer pipeline: MET-097i, our investigational ultra-long-acting, next-generation injectable GLP-1RA in chronic weight management (#obesity), and PF’4404 (SSGJ-707), our investigational PD-1x VEGF bispecific antibody in metastatic #colorectalcancer (CRC). These trials mark the first wave of the robust global development programs planned for each investigational candidate, which are expected to continue to expand across several indications and dosing regimens through 2026. We accelerated these pivotal programs after announcing the transactions last year, demonstrating how Pfizer can mobilize science, global operations, and partnerships to accelerate breakthroughs for patients. Milestones like these reflect the dedication of our investigators, colleagues, and—most importantly—the trust of the people who volunteer for clinical research. Thank you to everyone helping us advance the science with care and rigor.
-
Pfizer reposted this
Happy New Year! I spent the holiday with my family, but in the days before, a few emails from the team made my year. In December, we dosed the first participants in two Phase 3 trials: an investigational ultra-long-acting injectable peptide for chronic weight management, and an investigational antibody for advanced colorectal cancer. Both programs joined our pipeline just last year, from our agreements with Metsera and 3SBio, respectively. We then moved them into pivotal studies ahead of plan, with many more studies to come in 2026 — proving once again that nothing is impossible. I am so proud of our team. This is what Pfizer does best. We find the most promising science and accelerate development with the aim of bringing hope to patients faster. Millions are impacted by obesity and its comorbidities, and there is a troubling increase in colon and rectal cancer diagnosis in younger adults. These people deserve more options, and we are working to deliver. Thank you to everyone who made this happen, and to the participants who trust us by volunteering for vital clinical research.